Search

Marc A Gavin

from Seattle, WA
Age ~58
Get Report
Also known as:
Marca Gavin, Gavin Marca
Phone and address:
203 60Th St, Seattle, WA 98103
Related to:
Hsun C Chan, 58Benjamin P Gavin, 27
Connected to:
Aaron E Gavin, 74Agustin Gavin, 38Bennie Gavin, 66Bill T Gavin, 88Calvin R Gavin, 55Charlie Gavin, 42Christa L Gavin, 52Christian N Gavin, 54Ciara M Gavin, 47Dallas Gavin, 29

Marc Gavin Phones & Addresses

  • 203 60Th St, Seattle, WA 98103
  • 516 67Th St, Seattle, WA 98103 (206) 783-9608
  • 816 43Rd St, Seattle, WA 98103 (206) 545-7870
  • Bainbridge Island, WA
  • 9716 214Th Pl, Vashon, WA 98070 (206) 408-7419
  • Simsbury, CT
  • 11022 Palisades Ave SW, Vashon, WA 98070 (206) 408-7419

Work

Company: Benaroya research institute Mar 2018 Position: Affiliate investigator

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Washington 1990 to 1995 Specialities: Immunology, Philosophy

Skills

Drug Discovery • Biotechnology • Immunology • Cell Culture • Drug Development • Antibodies • Assay Development • Biochemistry • Cell Biology • Elisa • Protein Chemistry • Biopharmaceuticals

Industries

Biotechnology

Resumes

Resumes

Marc Gavin Photo 1

Director, Immunology

View page
Location:
1201 Ninth Ave, Seattle, WA
Industry:
Biotechnology
Work:
Benaroya Research Institute
Affiliate Investigator
Omeros Corporation
Director, Immunology
Benaroya Research Institute May 2015 - Mar 2018
Research Associate Member
Amgen 2006 - Apr 2015
Principal Scientist
University of Washington Oct 2000 - Oct 2006
Postdoctoral Fellow
Education:
University of Washington 1990 - 1995
Doctorates, Doctor of Philosophy, Immunology, Philosophy Princeton University 1985 - 1989
Bachelors, Molecular Biology
Skills:
Drug Discovery
Biotechnology
Immunology
Cell Culture
Drug Development
Antibodies
Assay Development
Biochemistry
Cell Biology
Elisa
Protein Chemistry
Biopharmaceuticals

Publications

Us Patents

Compositions And Methods Of Treating Inflammatory And Autoimmune Diseases

View page
US Patent:
20110274650, Nov 10, 2011
Filed:
Jan 20, 2010
Appl. No.:
13/145537
Inventors:
Marc A. Gavin - Vashon WA, US
Li Li - Sammamish WA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
A61K 38/20
A61P 11/06
A61P 3/10
C07K 14/55
A61P 37/08
A61P 37/06
C12N 5/0783
A61P 29/00
A61P 19/02
US Classification:
424 852, 435375, 530351
Abstract:
Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.

Interleukin-2 Muteins For The Expansion Of T-Regulatory Cells

View page
US Patent:
20210139554, May 13, 2021
Filed:
Oct 7, 2020
Appl. No.:
17/065395
Inventors:
- Thousand Oaks CA, US
Christy Ann THOMSON - Port Moody, British Columbia, CA
Marc Alain GAVIN - Seattle WA, US
Ian Nevin FOLTZ - Burnaby, British Columbia, CA
Dong XIA - Redmond WA, US
Dina N. ALCORN - Tacoma WA, US
Randal Robert KETCHEM - Snohomish WA, US
Ai Ching LIM - San Carlos CA, US
Kathy MANCHULENKO - Port Coquitlam, British Columbia, CA
Laura SEKIROV - Vancouver, British Columbia, CA
Kelly Ann BERRY - Port Coquitlam, British Columbia, CA
Cyr Clovis Chua DE IMUS - Kenmore WA, US
Neeraj Jagdish AGRAWAL - Natick MA, US
Gunasekaran KANNAN - Daly City CA, US
Li LI - San Bruno CA, US
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C07K 14/55
A61P 37/00
A61K 38/20
C07K 16/24
Abstract:
Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.

Methods And Compositions For Treating Cancer

View page
US Patent:
20200345725, Nov 5, 2020
Filed:
Jan 10, 2020
Appl. No.:
16/740187
Inventors:
- Seattle WA, US
Neil S. Cutshall - Snohomish WA, US
Gregory A. Demopulos - Mercer Island WA, US
George A. Gaitanaris - Seattle WA, US
Marc A. Gavin - Seattle WA, US
Alexander Gragerov - Seattle WA, US
Thomas L. Little - Seattle WA, US
Rene Onrust - Fall City WA, US
International Classification:
A61K 31/496
A61K 31/495
A61K 31/55
A61K 31/502
A61K 31/381
A61K 31/473
A61K 31/341
A61K 31/17
A61K 31/4409
A61P 35/00
A61K 45/06
C07K 16/28
A61K 39/395
A61K 31/53
G01N 33/574
A61K 31/519
A61K 31/506
A61K 31/522
Abstract:
This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).

Interleukin-2 Muteins For The Expansion Of T-Regulatory Cells

View page
US Patent:
20200024319, Jan 23, 2020
Filed:
May 4, 2016
Appl. No.:
15/565376
Inventors:
- Thousand Oaks CA, US
Marc Alain GAVIN - Seattle WA, US
Ian Nevin FOLTZ - Burnaby, CA
Dong XIA - Redmond WA, US
Dina N. ALCORN - Federal Way WA, US
Ai Ching LIM - San Carlos CA, US
Randal Robert KETCHUM - Snohomish WA, US
Kathy MANCHULENKO - Port Coquitlam, CA
Laura SEKIROV - Vancouver, CA
Kelly Ann BERRY - Port Coquitlam, CA
Cyr Clovis Chua DE IMUS - Kenmore WA, US
Neeraj Jagdish AGRAWAL - Thousand Oaks CA, US
Gunasekaran KANNAN - Daly City CA, US
Li LI - Sammamish WA, US
Assignee:
AMGEN INC. - Thousand Oaks CA
International Classification:
C07K 14/55
C07K 16/24
A61K 38/20
A61P 37/00
Abstract:
Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
Control profile
Marc A Gavin from Seattle, WA, age ~58 Get Report